Abstract
Background: Garenoxacin mesilate (GRNX) is a novel oral des-fluoro(6) quinolone with potent antimicrobial activity against common respiratory pathogens, including resistant strains. Some researchers showed high efficacy of GRNX for acute otolaryngological infectious diseases. However, there are few reports on its efficacy in the treatment of adult otitis media.
Objective: The aim of this study was to investigate the effectiveness of GRNX for adult otitis media.
Material and Method: We reviewed thirty adult patients with acute exacerbation of chronic otitis media and seven adult patients with acute otitis media from June 2008 to July 2009. We examined the clinical efficacy and biological response of GRNX in these patients.
Results: Clinical efficacy rates were 93% in acute exacerbation of chronic otitis media and 100% in acute otitis media. In acute exacerbation of chronic otitis media, bacteriological eradication rates were 9/12 in MSSA, 2/2 in MRSA, 1/2 in P. aeruginosa, 1/1 in P. mirabilis and 1/1 in S. marcescens. The overall eradication rate in acute exacerbation of chronic otitis media was 75%. In acute otitis media, four strains were isolated: CNS, S. pyogenes, M. catarrhalis and PSSP. These were all eradicated.
Conclusion: The clinical efficacy of GRNX for adult otitis media in this study was superior to those of previous reports. GRNX is very useful for the treatment of acute exacerbation of chronic otitis media and acute otitis media in adults.
